No connection

Search Results

AYTU vs LFWD

AYTU
Aytu BioPharma, Inc.
NEUTRAL
Price
$2.70
Market Cap
$27.5M
Sector
Healthcare
AI Confidence
65%
LFWD
Lifeward Ltd.
BEARISH
Price
$6.57
Market Cap
$24.9M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
AYTU
--
LFWD
--
Forward P/E
AYTU
15.88
LFWD
-5.21
P/B Ratio
AYTU
1.15
LFWD
1.19
P/S Ratio
AYTU
0.43
LFWD
1.13
EV/EBITDA
AYTU
3.86
LFWD
-0.71

Profitability

Gross Margin
AYTU
67.56%
LFWD
38.25%
Operating Margin
AYTU
-10.83%
LFWD
-112.69%
Profit Margin
AYTU
-20.52%
LFWD
-90.38%
ROE
AYTU
-50.23%
LFWD
-146.12%
ROA
AYTU
0.61%
LFWD
-40.97%

Growth

Revenue Growth
AYTU
-16.2%
LFWD
-32.7%
Earnings Growth
AYTU
--
LFWD
--

Financial Health

Debt/Equity
AYTU
1.23
LFWD
0.52
Current Ratio
AYTU
1.23
LFWD
1.31
Quick Ratio
AYTU
1.0
LFWD
0.69

Dividends

Dividend Yield
AYTU
--
LFWD
--
Payout Ratio
AYTU
0.0%
LFWD
0.0%

AI Verdict

AYTU NEUTRAL

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.

Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
LFWD BEARISH

LFWD exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9, indicating fundamental weakness across almost all health metrics. The company is experiencing a collapse in top-line growth with revenue declining by 32.7% YoY, coupled with an unsustainable operating margin of -112.69%. Despite a low Price/Book ratio, the massive negative ROE (-146.12%) and consistent earnings misses (0/4 in the last year) suggest a failing business model. The extreme disconnect between the current price ($6.57) and the analyst target ($20.00) is not supported by any available fundamental data.

Strengths
Positive Gross Margin (38.25%)
Low Debt/Equity ratio (0.52) relative to sector average
Current Ratio above 1.0 (1.31)
Risks
Severe revenue contraction (-32.7% YoY)
Extreme profitability decay (Profit Margin -90.38%)
Critical Piotroski F-Score (1/9) signaling high risk

Compare Another Pair

AYTU vs LFWD: Head-to-Head Comparison

This page compares Aytu BioPharma, Inc. (AYTU) and Lifeward Ltd. (LFWD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile